Literature DB >> 18653333

4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors.

Guozhang Xu1, Marta C Abad, Peter J Connolly, Michael P Neeper, Geoffrey T Struble, Barry A Springer, Stuart L Emanuel, Niranjan Pandey, Robert H Gruninger, Mary Adams, Sandra Moreno-Mazza, Angel R Fuentes-Pesquera, Steven A Middleton.   

Abstract

Members of a novel class of 4-amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones were identified as potent dual ErbB-2/EGFR kinase inhibitors using concept-guided design approach. These compounds inhibited the growth of ErbB-2 over-expressing human tumor cell lines (BT474, N87, and SK-BR-3) in vitro. Compound 15 emerged as a key lead and showed significant ability to inhibit growth factor-induced receptor phosphorylation in SK-BR-3 cells (IC(50)=54 nM) and cellular proliferation in vitro (IC(50)=14, 58, and 58 nM for BT474, N87, and SK-BR-3 respectively). The X-ray co-crystal structure of EGFR with a close analog (17) was determined and validated our design rationale.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18653333     DOI: 10.1016/j.bmcl.2008.07.020

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  14 in total

1.  Statistical analysis of EGFR structures' performance in virtual screening.

Authors:  Yan Li; Xiang Li; Zigang Dong
Journal:  J Comput Aided Mol Des       Date:  2015-10-17       Impact factor: 3.686

2.  Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating phospho-Src-Y416 and phospho-EGFR-Y1173.

Authors:  Lu Kong; Zhihong Deng; Haiying Shen; Yuxiang Zhang
Journal:  Mol Cell Biochem       Date:  2010-11-04       Impact factor: 3.396

3.  In silico screening of epidermal growth factor receptor (EGFR) in the tyrosine kinase domain through a medicinal plant compound database.

Authors:  Orathai Sawatdichaikul; Supa Hannongbua; Chak Sangma; Peter Wolschann; Kiattawee Choowongkomon
Journal:  J Mol Model       Date:  2011-06-29       Impact factor: 1.810

4.  Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay.

Authors:  Yanli Ma; Bingli Qi; Meiying Ning; Lijuan Zhang; Zeyu An; Jing Zhao
Journal:  Eur Biophys J       Date:  2022-03-21       Impact factor: 1.733

5.  DOCK 6: Impact of new features and current docking performance.

Authors:  William J Allen; Trent E Balius; Sudipto Mukherjee; Scott R Brozell; Demetri T Moustakas; P Therese Lang; David A Case; Irwin D Kuntz; Robert C Rizzo
Journal:  J Comput Chem       Date:  2015-06-05       Impact factor: 3.376

6.  Comparison of anti-inflammatory mechanisms of mango (Mangifera Indica L.) and pomegranate (Punica Granatum L.) in a preclinical model of colitis.

Authors:  Hyemee Kim; Nivedita Banerjee; Ivan Ivanov; Catherine M Pfent; Kalan R Prudhomme; William H Bisson; Roderick H Dashwood; Stephen T Talcott; Susanne U Mertens-Talcott
Journal:  Mol Nutr Food Res       Date:  2016-05-23       Impact factor: 5.914

7.  Schiff bases of indoline-2,3-dione (isatin) with potential antiproliferative activity.

Authors:  Tarek Aboul-Fadl; Awwad A Radwan; Mohamed I Attia; Abdullah Al-Dhfyan; Hatem A Abdel-Aziz
Journal:  Chem Cent J       Date:  2012-05-30       Impact factor: 4.215

8.  Co-conserved features associated with cis regulation of ErbB tyrosine kinases.

Authors:  Amar Mirza; Morad Mustafa; Eric Talevich; Natarajan Kannan
Journal:  PLoS One       Date:  2010-12-13       Impact factor: 3.240

9.  Identifying HER2 inhibitors from natural products database.

Authors:  Shun-Chieh Yang; Su-Sen Chang; Calvin Yu-Chian Chen
Journal:  PLoS One       Date:  2011-12-12       Impact factor: 3.240

10.  Synthesis, potential antitumor activity, cell cycle analysis, and multitarget mechanisms of novel hydrazones incorporating a 4-methylsulfonylbenzene scaffold: a molecular docking study.

Authors:  Alaa A-M Abdel-Aziz; Adel S El-Azab; Nawaf A AlSaif; Ahmad J Obaidullah; Abdulrahman M Al-Obaid; Ibrahim A Al-Suwaidan
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.